{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:27:27Z","timestamp":1777728447281,"version":"3.51.4"},"reference-count":33,"publisher":"Medical Association of Nippon Medical School","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2025,4,20]]},"DOI":"10.1272\/jnms.jnms.2025_92-211","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T22:10:53Z","timestamp":1747779053000},"page":"196-203","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of the Optimal Interval of Perioperative Serum Flomoxef Administration in Hepatobiliary-Pancreatic Surgery"],"prefix":"10.1272","volume":"92","author":[{"given":"Yoko","family":"Takayama","sequence":"first","affiliation":[{"name":"Department of Infection Control and Infectious Diseases, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine"},{"name":"Department of Infection Control and Prevention, Kitasato University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Tsumuraya","sequence":"additional","affiliation":[{"name":"Sogo Medical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kaizu","sequence":"additional","affiliation":[{"name":"Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"Department of General-Pediatric-Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Hanaki","sequence":"additional","affiliation":[{"name":"Infection Control Research Center, The Omura Satoshi Memorial Institution, Kitasato University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Darlow CA, da Costa RMA, Ellis S, et al. Potential antibiotics for the treatment of neonatal sepsis caused by multidrug resistant bacteria. Paediatr Drugs. 2021 Sep;23 (5):465-84. doi: 10.1007\/s40272-021-00465-z","DOI":"10.1007\/s40272-021-00465-z"},{"key":"2","unstructured":"2. Shionogi &amp; Co., Ltd.. [FLUMARIN<sup>\u00ae<\/sup> for Intravenous Injection\/Kits] [Internet]. Osaka: Shionogi &amp; Co., Ltd.; 2023 Nov. [cited 2023 Nov]. Available from: http:\/\/med.shionogi.co.jp\/products\/medicine\/flumarin\/interview-form_pdf.html. Japanese."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016 Dec;29 (6):583-94. doi: 10.1097\/QCO.0000000000000314","DOI":"10.1097\/QCO.0000000000000314"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017 Feb 28;543 (7643):15. doi: 10.1038\/nature.2017.21550","DOI":"10.1038\/nature.2017.21550"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol. 2018 Jul;61:185-8. doi: 10.1016\/j.meegid.2018.04.005","DOI":"10.1016\/j.meegid.2018.04.005"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Lee CH, Su LH, Chen FJ, et al. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study. Int J Antimicrob Agents. 2015 Dec;46 (6):610-5. doi: 10.1016\/j.ijantimicag.2015.07.020","DOI":"10.1016\/j.ijantimicag.2015.07.020"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015 Sep;59 (9):5107-13. doi: 10.1128\/AAC.00701-15","DOI":"10.1128\/AAC.00701-15"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Lee CH, Chen IL, Li CC, Chien CC. Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia. Infect Drug Resist. 2018 Feb 23;11:257-66. doi: 10.2147\/IDR.S146923","DOI":"10.2147\/IDR.S146923"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26 (1):1-10; quiz 11-2. doi: 10.1086\/516284","DOI":"10.1086\/516284"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Craig WA. Does the dose matter? Clin Infect Dis. 2001 Sep 15;33 (Suppl 3):S233-7. doi: 10.1086\/321854","DOI":"10.1086\/321854"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Komatsu T, Tsumuraya S, Takayama Y, et al. Population pharmacokinetic-pharmacodynamic target attainment analysis of flomoxef in the serum and liver tissue of patients undergoing hepatic resection. Antimicrob Agents Chemother. 2022 Apr 19;66 (4):e0230321. doi: 10.1128\/aac.02303-21","DOI":"10.1128\/aac.02303-21"},{"key":"12","unstructured":"12. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961 Jul;50:161-8. doi: 10.5555\/uri:pii:0039606061900198"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Takayama Y, Komatsu T, Nakamura T, et al. Association of serum and fat tissue antibiotic concentrations with surgical site infections in lower gastrointestinal surgery. Surgery. 2022 Apr;171 (4):1000-5. doi: 10.1016\/j.surg.2021.10.013","DOI":"10.1016\/j.surg.2021.10.013"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Sheikh S, Swapnil K, Tripathi CD, Meshram GG, Karim BA. Intra-operative drug level monitoring of pre-operative antibiotic for surgical prophylaxis in the patients of elective spinal surgery. J Basic Clin Physiol Pharmacol. 2023 Sep 11;34 (6):797-804. doi: 10.1515\/jbcpp-2023-0104","DOI":"10.1515\/jbcpp-2023-0104"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013 Feb;14 (1):73-156. doi: 10.1089\/sur.2013.9999","DOI":"10.1089\/sur.2013.9999"},{"key":"16","unstructured":"16. Albacker TB, Alqattan H, Alqahtani SA, et al. Serum level of prophylactic antibiotics in cardiac surgery and its implication on surgical site infection (SSI). Am J Cardiovasc Dis [Internet]. 2022 Aug 15;12 (4):233-9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9490157\/pdf\/ajcd0012-0233.pdf"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Togo S, Tanaka K, Matsuo K, et al. Duration of antimicrobial prophylaxis in patients undergoing hepatectomy: a prospective randomized controlled trial using flomoxef. J Antimicrob Chemother. 2007 May;59 (5):964-70. doi: 10.1093\/jac\/dkm028","DOI":"10.1093\/jac\/dkm028"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Shinkawa H, Tanaka S, Takemura S, et al. Giving short-term prophylactic antibiotics in patients undergoing open and laparoscopic hepatic resection. Ann Gastroenterol Surg. 2019 May 30;3 (5):506-14. doi: 10.1002\/ags3.12267","DOI":"10.1002\/ags3.12267"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg. 2011 Jun;253 (6):1082-93. doi: 10.1097\/SLA.0b013e31821175f8","DOI":"10.1097\/SLA.0b013e31821175f8"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Yamamoto M, Jimbo M, Ide M, Tanaka N, Umebara Y, Hagiwara S. Perioperative antimicrobial prophylaxis in neurosurgery: clinical trial of systemic flomoxef administration and saline containing gentamicin for irrigation. Neurol Med Chir (Tokyo). 1996 Jun;36 (6):370-6. doi: 10.2176\/nmc.36.370","DOI":"10.2176\/nmc.36.370"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017 Aug 1;152 (8):784-91. doi: 10.1001\/jamasurg.2017.0904","DOI":"10.1001\/jamasurg.2017.0904"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Hamada Y, Kasai H, Suzuki-Ito M, Matsumura Y, Doi Y, Hayakawa K. Pharmacokinetic\/pharmacodynamic analysis and dose optimization of cefmetazole and flomoxef against extended-spectrum \u03b2-lactamase-producing Enterobacterales in patients with invasive urinary tract infection considering renal function. Antibiotics (Basel). 2022 Mar 28;11 (4):456. doi: 10.3390\/antibiotics11040456","DOI":"10.3390\/antibiotics11040456"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Sadahiro S, Suzuki T, Tanaka A, et al. Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. Surgery. 2014 Mar;155 (3):493-503. doi: 10.1016\/j.surg.2013.06.002","DOI":"10.1016\/j.surg.2013.06.002"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun;36 (5):309-32. doi: 10.1016\/j.ajic.2008.03.002","DOI":"10.1016\/j.ajic.2008.03.002"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Takahashi Y, Takesue Y, Fujiwara M, et al. Risk factors for surgical site infection after major hepatobiliary and pancreatic surgery. J Infect Chemother. 2018 Sep;24 (9):739-43. doi: 10.1016\/j.jiac.2018.05.007","DOI":"10.1016\/j.jiac.2018.05.007"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Mentor K, Ratnayake B, Akter N, et al. Meta-analysis and meta-regression of risk factors for surgical site infections in hepatic and pancreatic resection. World J Surg. 2020 Dec;44 (12):4221-30. doi: 10.1007\/s00268-020-05741-6","DOI":"10.1007\/s00268-020-05741-6"},{"key":"27","unstructured":"27. Yamaguchi K, Ishii Y, Tateda K, et al. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012]. Jpn J Antibiot. 2014 Apr;67 (2):73-107. Japanese."},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Riggi G, Castillo M, Fernandez M, et al. Improving compliance with timely intraoperative redosing of antimicrobials in surgical prophylaxis. Infect Control Hosp Epidemiol. 2014 Oct;35 (10):1236-40. doi: 10.1086\/678058","DOI":"10.1086\/678058"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Vercheval C, Sadzot B, Maes N, Denooz R, Damas P, Frippiat F. Continuous infusion of cefepime and neurotoxicity: a retrospective cohort study. Clin Microbiol Infect. 2020 Jul 9;S1198-743X(20)30386-4. doi: 10.1016\/j.cmi.2020.07.003","DOI":"10.1016\/j.cmi.2020.07.003"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious neurological adverse events of ceftriaxone. Antibiotics (Basel). 2021 May 6;10 (5):540. doi: 10.3390\/antibiotics10050540","DOI":"10.3390\/antibiotics10050540"},{"key":"31","unstructured":"31. Ministry of Health, Labour and Welfare, Japan Nosocomial Infections Surveillance. [SSI Division JANIS Annual Open Report 2021] [Internet]. 2022 Aug 12. [cited 2022 May 30]. Available from: https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fjanis.mhlw.go.jp%2Freport%2Fopen_report%2F2021%2F3%2F5%2FSSI_Open_Report_202100.xls&amp;wdOrigin=BROWSELINK. Japanese."},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Tod M, Lagneau F, Jullien V, Mimoz O. A physiological model to evaluate drug kinetics in patients with hemorrhagic shock followed by fluid resuscitation. Application to amoxicillin-clavulanate. Pharm Res. 2008 Jun;25 (6):1431-9. doi: 10.1007\/s11095-008-9546-y","DOI":"10.1007\/s11095-008-9546-y"},{"key":"33","unstructured":"33. Kimura Y, Nakashimizu H, Nakano M, et al. [Pharmacokinetic characterization of 6315-S (flomoxef) in experimental animals]. Jpn J Chemother. 1987;35 (S-1):161-75. Japanese."}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/92\/2\/92_JNMS.2025_92-211\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:40:57Z","timestamp":1748061657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/92\/2\/92_JNMS.2025_92-211\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,20]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2025_92-211","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,20]]},"article-number":"JNMS.2025_92-211"}}